Eli Lilly and Company

Company3 list appearances

**Identity and History** Eli Lilly and Company (NYSE: LLY; CIK: 0000059478) is an American multinational pharmaceutical corporation headquartered at Lilly Corporate Center in Indianapolis, Indiana. The company was founded on May 10, 1876 in Indianapolis by Colonel Eli Lilly, a pharmaceutical chemist and Union Army veteran of the American Civil War committed to manufacturing scientifically standardized prescription medicines. Formally incorporated under the laws of the State of Indiana on January 17, 1901, Lilly pioneered commercial mass production of insulin in the 1920s, polio vaccines and antibiotics in the mid-20th century, and blockbuster psychiatric and metabolic therapies including Prozac, Humalog, and Trulicity, before becoming the world's first trillion-dollar healthcare company on the strength of its next-generation incretin franchise. **What the Company Does** Lilly discovers, develops, manufactures, and markets medicines within a single reportable business segment—human pharmaceutical products—organized commercially and scientifically around four core therapeutic areas: Cardiometabolic Health, Oncology, Immunology, and Neuroscience. Its growth engine is anchored by dual GIP/GLP-1 receptor agonist tirzepatide, marketed globally as **Mounjaro** for type 2 diabetes ($10.7 billion in Q3 2026 revenue alone, +65% YoY) and **Zepbound** for chronic weight management and moderate-to-severe obstructive sleep apnea ($5.3 billion in Q3 2026 U.S. revenue, +48% YoY), now joined by oral small-molecule GLP-1 agonist **Foundayo** (orforglipron) and **Onswik**. Beyond metabolic medicine, Lilly markets key products **Verzenio**, **Jaypirca**, and **Inluriyo** in oncology; **Taltz**, **Ebglyss**, and **Omvoh** in immunology; and **Kisunla** (donanemab) for early symptomatic Alzheimer's disease. In the United States, Lilly distributes primarily through three major wholesale distributors (McKesson, Cencora, and Cardinal Health) while rapidly scaling its direct-to-consumer digital healthcare and pharmacy platform, **LillyDirect**. **Scale and Market Position** Eli Lilly is the largest pharmaceutical and healthcare corporation globally by market capitalization. In FY2025 (ended December 31, 2025), consolidated revenue surged 45% year-over-year to $65,179 million (up from $45,043 million in FY2024), while GAAP net income nearly doubled (+95%) to $20,640 million ($22.95 diluted EPS). Expansion accelerated through the first nine months of 2026 (ended September 30, 2026), with 9M 2026 revenue climbing 46% to $67,170 million (exceeding all of FY2025 in three quarters) and 9M 2026 GAAP net income reaching $20,942 million. On a trailing twelve-month (TTM) basis ended September 30, 2026, Lilly generated $86.46 billion in revenue, $27.58 billion in GAAP net income, and $30.65 billion in operating cash flow ($19.66 billion free cash flow after $10.98 billion in capital expenditures to expand manufacturing capacity). In Q3 2026, Lilly held a 63.0% share of the U.S. incretin analogs market and ~58.4% international incretin market share. As of December 31, 2025, Lilly employed approximately 50,000 people worldwide, and as of November 7, 2026 led 240 active clinical trials (including 102 Phase 3 trials). Across November 9–12, 2026, Lilly's market capitalization ranged from $1.27 trillion to $1.352 trillion (with an enterprise value of $1.31 trillion as of November 9–10, 2026), ranking #1 among global biopharma peers—nearly double second-place Johnson & Johnson (~$676B–$679B)—and #10 among all U.S. public companies. **Leadership and Ownership** David A. Ricks serves as Chair of the Board, President, and Chief Executive Officer, alongside Lead Independent Director Juan R. Luciano. Key executive officers include Lucas E. Montarce (EVP and Chief Financial Officer), Daniel Skovronsky (EVP, Chief Scientific and Product Officer), Anat Hakim (EVP, General Counsel and Secretary), Edgardo Hernandez (EVP and President, Manufacturing Operations), Ilya Yuffa (EVP and President, Lilly USA), and Patrik Jonsson (EVP and President, Lilly International). Lilly has a single class of voting no-par-value common stock, with 940,745,031 shares reported on the Q3 2026 Form 10-Q cover page (approximately 890.75 million shares outstanding excluding treasury shares held for employee benefit trusts in market-data computations). Institutional ownership stands at roughly 89.55%, anchored historically by **Lilly Endowment Inc.**—the independent Indianapolis philanthropic

Frequently Ranked Alongside Eli Lilly and Company

NVIDIA Corporation

3 shared lists

Microsoft Corporation

3 shared lists

Amazon.com, Inc.

3 shared lists

Tesla

3 shared lists

Apple

2 shared lists

Broadcom (AVGO)

2 shared lists

Meta Platforms, Inc.

1 shared list

Berkshire Hathaway

1 shared list